[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-disease":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,50,85,114,139,169,199,232,257,285,308,329,357,381,404,443,471,493,516,541,573,603,630,656,684],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100054173","maternal-periodontal-inflammation-and-pregnancy-outcomes-salivary-and-amniotic-biomarkers-100054173",false,"NCT07699978","Maternal Periodontal Inflammation and Pregnancy Outcomes: Salivary and Amniotic Biomarkers","The Relationship Between Maternal Periodontal Inflammation and Pregnancy Outcomes: Evaluation Using Inflammatory and Oxidative Stress Biomarkers in Saliva and Amniotic Fluid","Inclusion Criteria:\n\nPregnant women between 28 and 32 weeks of gestation Age 18 to 40 years Singleton pregnancy Systemically healthy Normal gestational diabetes screening (oral glucose tolerance test within the hospital reference range) Receiving only routine prenatal vitamin and iron supplementation (no therapeutic medications) Low-risk pregnancy No history of chorioamnionitis No periodontal treatment within the previous 6 months Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nMultiple pregnancy Use of antibiotics or anti-inflammatory medications during pregnancy Current smoking or alcohol consumption Presence of an acute infection Placental pathology Major fetal anomaly High-risk pregnancy as determined by the obstetrician Refusal or inability to provide informed consent",true,"FEMALE","18 Years","40 Years",{"count":22,"type":23},80,"ESTIMATED","OBSERVATIONAL","Periodontal disease is a chronic inflammatory condition that affects the tissues supporting the teeth and may contribute to systemic inflammation and oxidative stress. Increasing evidence suggests that maternal inflammation during pregnancy may be associated with adverse pregnancy outcomes, including preterm birth. However, the biological mechanisms linking maternal periodontal inflammation to the intrauterine environment remain unclear.\n\nThis prospective observational cohort study aims to investigate the relationship between maternal periodontal status and inflammatory and oxidative stress biomarkers measured in both saliva and amniotic fluid. Eighty healthy pregnant women between 28 and 32 weeks of gestation will be recruited from the Obstetrics and Gynecology Clinic of Gulhane Training and Research Hospital. Participants will undergo a comprehensive periodontal examination and provide unstimulated saliva samples. Amniotic fluid samples will be collected during delivery as part of routine obstetric care, without any additional invasive procedures.\n\nThe concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), interleukin-6 (IL-6), and matrix metalloproteinase-8 (MMP-8) will be measured in saliva and amniotic fluid using enzyme-linked immunosorbent assay (ELISA). Pregnancy outcomes, including gestational age at delivery, birth weight, and pregnancy complications, will also be recorded.\n\nThe study will evaluate whether maternal periodontal inflammation is associated with changes in inflammatory and oxidative stress biomarkers in saliva and amniotic fluid and whether these biomarkers are related to pregnancy outcomes. The findings may improve understanding of the biological relationship between oral health and pregnancy and may contribute to the identification of biomarkers associated with adverse pregnancy outcomes.",[27,28,29],"Periodontal Disease","Pregnancy","Preterm Birth",[31,28,29,32,33,34,35,36,37],"Periodontitis","Oxidative Stress","Inflammation","Saliva","Amniotic Fluid","8-Hydroxy-2'-deoxyguanosine (8-OHdG)","Interleukin-6 (IL-6)","NOT_YET_RECRUITING","2026-07-07",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":23},"2026-08-20",{"date":46,"type":23},"2027-08-15",{"name":48,"class":49},"Saglik Bilimleri Universitesi","OTHER",{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":4,"leadSponsor":81,"locationsCount":84},"100176270","oral-bacteria-and-immune-system-problems-involved-in-gum-disease-periodontitis-100176270","NCT01568697","Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)","Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction","* INCLUSION CRITERIA:\n\nSubjects with Genetic Immune Defects:\n\nPatients with a known genetic immune defect will be eligible for screening inclusion under this protocol.\n\n* Diagnosed with a genetic immune defect\n* Willing to allow genetic testing\n\n  * 7 years old\n\nSubjects with Severe Periodontitis of Suspected Genetic Etiology:\n\n* History of severe periodontitis prior to age \\\u003C30\n* Willing to allow genetic testing\n\n  -\\>=7 years old\n* In good general health\n\nFamily members of Subjects with Severe Periodontitis of Suspected Genetic Etiology:\n\n-Willing to allow genetic testing\n\n-\\>=7 years old\n\nHealthy Volunteer Subjects (with\u002Fwithout periodontitis):\n\n* In good general health\n\n  -\\>=18 years old\n* Willing to allow genetic testing\n* Have a minimum of 20 natural teeth\n\nInclusion Criteria for Natural History phase, all subjects:\n\n* Diagnosis of genetic immune defect\n* Presence of oral manifestation (primarily periodontitis)\n\nCriteria for standard of care treatment:\n\n* Active untreated disease (visible signs of tissue inflammation including erythema\u002Fedema, generalized bleeding upon probing)\n* Periodontal disease defined as bone loss of \\>=5mm as measured on periodontal exam.\n\nEXCLUSION CRITERIA:\n\nAll Subjects:\n\n* History of Hepatitis B or C\n* History of HIV\n* Prior radiation therapy to the head or neck\n* Have an active malignancy except localized basal or squamous cell carcinoma of the skin\n* Have been treated with systemic chemotherapeutics or radiation therapy within 5 years of screening\n* Pregnant or lactating\n* If participation in the protocol would not be safe or in the subject s best interest in the opinion of either the PI or the primary medical team.\n\nAdditional Exclusions for Healthy Volunteers:\n\n* Diagnosis of diabetes and\u002For HbA1C level \\>6%\n* More than 3 hospitalizations in the last 3years\n* Have an autoimmune disorder such as Lupus, Rheumatoid arthritis, etc.\n* In the 3 months before study enrollment, have used any of the following:\n\n  * Systemic (intravenous, intramuscular, or oral) antibiotics\n  * Oral, intravenous, intramuscular, intranasal, or inhaled corticosteroids or other immunosuppressants (e.g., cyclosporine)\n  * Cytokine therapy\n  * Methotrexate or immunosuppressive chemotherapeutic agents\n  * Large doses of commercial probiotics (\\>=10\\^8 colony-forming units or organisms per day); includes tablets, capsules, lozenges, chewing gum, or powders in which a probiotic is a primary component; ordinary dietary components such as fermented beverages\u002Fmilks, yogurts, and foods do not apply\n* Have used tobacco products (including e-cigarettes) within 1 year of screening\n* Unwillingness to consent to oral biopsy\n* NIH employees working in the Oral Immunity and Inflammation Unit and members of the Clinical Research Core Team will not be eligible for enrollment.\n\nAdditional Exclusions for Standard of Care Treatment at NIH:\n\n* Mild\u002Fmoderate non-active disease (absence of active inflammatory lesions)\n* Subjects with urgent\u002Fcomplex restorative needs (ex. severe active carious lesions\u002Ffractured dentition)\n* Subjects in need for advanced prosthetic needs (including implants and restorations)","ALL","7 Years","100 Years",{"count":61,"type":23},700,"Background:\n\n\\- Gum disease is a condition in which the tissue around the tooth root becomes swollen and infected. This condition can cause tooth loss if it is not treated. Who gets gum disease and how bad it will be depends on (1) the different bacteria in the mouth and (2) how the immune system of an individual handles these bacteria. Researchers want to look at the oral bacteria and genetic immune problems of different people to learn how these affect gum disease and other conditions of the mouth.\n\nObjectives:\n\n\\- To study how immune system problems may lead to problems in the mouth, including gum disease.\n\nEligibility:\n\n* Children and adults at least 7 years of age who have genetic problems with their immune system.\n* Healthy adults that have periodontal disease\n* Health adults that do not have periodontal disease\n\nDesign:\n\n* This study will involve a screening visit and a study visit.\n* Participants will be screened with a medical history, blood work and a full oral and dental exam, including dental x-rays and photos.\n* The study visit will involve collection of blood, urine, and other samples, including saliva, plaque, and gum swabs. Any abnormal tissue will sampled for a biopsy. Additional oral and dental exams will be performed. Participants will also answer questions about any current medical or dental problems.",[64,27,65,66],"Immunosuppression","Healthy Subjects","Healthy Volunteer",[68,31,69,70,71,72,27,73,66,74],"Microbiome","Oral Mucosal Immunity","Oral Infection","Natural History","Immune Disorder","Gum Disease","HV","RECRUITING","2026-06-27",{"date":78,"type":42},"2026-06-30",{"date":80,"type":42},"2012-10-05",{"name":82,"class":83},"National Institute of Dental and Craniofacial Research (NIDCR)","NIH",1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":17,"sex":57,"minAge":92,"maxAge":20,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":84},"100644467","early-phase-1-comparison-of-the-efficacy-of-conventional-versus-minimally-invasive-non-surgical-periodontal-therapy-in-periodontitis-patients-100644467","NCT07671274","Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patients","Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patients (Randomized Controlled Clinical Trial)","Inclusion Criteria:\n\n* • Patients with stage III pericdontitis, according to the American Academy of Periodontology (AAP) and the European Federation of Periodontology (EFP) periodontal classification system .\n\n  * Medically free patients.\n  * Non-smokers\n  * Patients with good oral hygiene.\n\nExclusion Criteria:\n\n* Pregnant or lactating females.\n\n  * Patients with systemic diseases that might affect periodontal health\n  * previous periodontal treatment within 6 months before baseline examination.\n  * prior antibiotic regimen use within 1 month before baseline examination","20 Years",{"count":94,"type":23},30,"INTERVENTIONAL",[97],"EARLY_PHASE1","the aim of this study is to investigate the clinical outcomes of Minimally Invasive Non-Surgical Therapy(MINST) compared to Conventional non-surgical periodontal therapy (CNST)",[27,100],"Stage III Periodontitis",[102,103,104],"periodontitis","stage III","mechanical debridement","2026-06-24",{"date":107,"type":42},"2026-06-26",{"date":109,"type":42},"2025-08-05",{"date":111,"type":23},"2026-08-05",{"name":113,"class":49},"Mansoura University",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":95,"phases":124,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":84},"100644529","effects-of-adjunctive-synbiotic-supplementation-to-non-surgical-periodontal-therapy-in-smokers-with-periodontitis-100644529","NCT07672379","Effects of Adjunctive Synbiotic Supplementation to Non-Surgical Periodontal Therapy in Smokers With Periodontitis","Effects of Adjunctive Synbiotic Supplementation to Non-Surgical Periodontal Therapy on Clinical, Immunological, and Microbiological Parameters in Smokers With Periodontitis","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of generalized Stage III\u002FIV Grade B\u002FC periodontitis\n* Willingness to participate in the study and provide informed consent\n* No periodontal treatment within the last 3 months\n* No use of antibiotics or anti-inflammatory drugs within the last 3 months\n* Not being pregnant or breastfeeding\n* Presence of at least 20 teeth\n* Body mass index (BMI) between 18.5 and 30 kg\u002Fm²\n\nExclusion Criteria:\n\n* Failure to meet voluntary participation requirements\n* Presence of systemic diseases affecting the periodontium or immune response\n* Use of additional dietary supplements\n* Pregnancy or breastfeeding\n* Use of immunosuppressive medications Individuals who may have difficulty complying with the study protocol","65 Years",{"count":123,"type":23},92,[125],"NA","The aim of this study is to evaluate the effects of adjunctive synbiotic supplementation combined with non-surgical periodontal therapy in smokers with periodontitis. The main questions this study aims to answer are:\n\nDoes adjunctive synbiotic supplementation improve clinical periodontal parameters in smokers with periodontitis? Does adjunctive synbiotic supplementation affect immunological and microbiological parameters associated with periodontal disease?\n\nSystemically healthy smokers and non-smokers diagnosed with generalized Stage III-IV Grade B\u002FC periodontitis will be included in the study. Participants will first be divided into two main groups according to smoking status (smokers and non-smokers). These groups will then be further divided into two subgroups according to the use of synbiotic or placebo capsules. Therefore, the study will consist of four groups in total. The sample size of the study was determined as 92 participants, with 23 participants included in each group.\n\nAll participants will receive non-surgical periodontal therapy (NSPT) at baseline. In addition to NSPT, participants will use either synbiotic or placebo capsules once daily for 90 days.\n\nTo evaluate clinical periodontal, immunological, and microbiological parameters, periodontal measurements will be performed, and saliva and subgingival plaque samples will be collected. In addition, stool samples will be collected from participants to evaluate the effects of synbiotic supplementation on the gastrointestinal microbiota, and microbiota analyses will be performed.\n\nAll samples will be collected again and evaluated at the third month following non-surgical periodontal therapy.",[27],[31,129,130,131],"Non-surgical periodontal treatment","Synbiotic","Probiotic",{"date":107,"type":42},{"date":134,"type":23},"2026-07-06",{"date":136,"type":23},"2027-10-06",{"name":138,"class":49},"Biruni University",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":149,"conditions":150,"keywords":158,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":84},"100638972","periodontal-disease-in-rare-renal-disorders-perio-ra-re-100638972","NCT07575347","Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)","Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease","PERIO-RA-RE","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* At least 10 natural teeth present\n* Belonging to one of the predefined study groups:\n\n  1. Alport syndrome (genetically or clinically confirmed)\n  2. Fabry disease (enzymatically or genetically confirmed)\n  3. Tuberous sclerosis complex (according to established clinical or genetic criteria)\n  4. Systemic lupus erythematosus defined according to the 2019 EULAR\u002FACR or SLICC 2012 classification criteria, with renal involvement defined by at least one of the following: \\[1\\] Biopsy-proven lupus nephritis, \\[2\\] Persistent proteinuria (\\>0.5 g\u002Fday or equivalent), \\[3\\] Active urinary sediment (hematuria and\u002For cellular casts) consistent with lupus nephritis\n  5. Chronic kidney disease (CKD) of non-rare etiology: defined according to KDIGO criteria (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² and\u002For markers of kidney damage)\n  6. Individuals without CKD, recruited from clinical or dental care settings as non-CKD controls\n\nExclusion Criteria:\n\n* Periodontal treatment within the last 6 months\n* Antibiotic therapy within the last 4 weeks\n* Pregnancy\n* Conditions precluding periodontal examination\n* Inability to comply with study procedures",{"count":148,"type":23},100,"This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.\n\nThis is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.\n\nThe primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.\n\nExploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.",[27,31,151,152,153,154,155,156,157],"CKD","Chronic Kidney Disease","Alport Syndrome","Fabry Disease","Lupus or SLE","Tuberous Sclerosis Complex (TSC)","Systemic Lupus Erythematosus (SLE)",[27,31,151,159,160,161,156,152],"Rare Kidney Diseases","Alport syndrome","Systemic Lupus Erythematosus",{"date":107,"type":42},{"date":164,"type":42},"2026-05-04",{"date":166,"type":23},"2027-12-31",{"name":168,"class":49},"Stefan Lujinschi",{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":57,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":95,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":84},"100644677","omega-3-plus-low-dose-aspirin-in-smokers-with-stage-iii-periodontitis-100644677","NCT07673185","Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis","Clinical and Biochemical Evaluation of the Effect of Omega-3 Fatty Acids Plus Low-Dose Aspirin as an Adjunct to Non-Surgical Periodontal Therapy in Smoker Patients With Stage III Periodontitis: A Randomized Double-Blind Placebo-Controlled Clinical Trial","OASP","Inclusion Criteria:\n\n* \\- Male or female smokers aged 30 to 50 years.\n* Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.\n* Probing pocket depth (PPD) ≥ 5 mm.\n* Clinical attachment loss (CAL) ≥ 5 mm.\n* Presence of at least 20 natural teeth.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* \\- Systemic diseases affecting periodontal health.\n* Pregnancy or lactation.\n* Periodontal treatment within the previous 6 months.\n* Use of antibiotics or anti-inflammatory drugs within the previous 6 months.\n* Allergy or hypersensitivity to omega-3 fatty acids or aspirin.\n* Long-term anticoagulant therapy.\n* History of gastric ulcer or bleeding disorders.\n* Participation in another clinical trial within the previous 3 month","30 Years","50 Years",{"count":180,"type":23},40,[125],"This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment",[27,184,185],"Periodontitis (Stage 3)","Smoking Behaviors",[187,188,189],"omega 3","smoker","stage 3","2026-06-23",{"date":192,"type":42},"2026-06-29",{"date":194,"type":42},"2025-01-15",{"date":196,"type":23},"2026-10-30",{"name":198,"class":49},"Al-Azhar University",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":17,"sex":57,"minAge":19,"maxAge":121,"enrollmentInfo":207,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":84},"100641785","salivary-biomarkers-in-periodontal-disease-progression-100641785","NCT07661784","Salivary Biomarkers in Periodontal Disease Progression","Evaluation of Salivary Biomarkers Associated With Bone Remodeling in the Transition From Periodontal Health to Disease","PERIO-BIO","Inclusion Criteria:\n\nAdults aged 18-65 years Systemically healthy individuals Individuals classified as periodontally healthy, gingivitis, or periodontitis according to clinical periodontal examination Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\nPresence of systemic diseases affecting periodontal status (e.g., diabetes mellitus, immunological disorders) Use of antibiotics or anti-inflammatory drugs within the last 3 months History of periodontal treatment within the last 6 months Pregnancy or lactation Smoking (optional ) Any condition that may affect salivary biomarker levels",{"count":208,"type":23},240,"This study aims to evaluate salivary biomarkers associated with bone remodeling during the transition from periodontal health to disease. Periodontal diseases are characterized by chronic inflammation that can lead to connective tissue destruction and alveolar bone loss. Although diagnosis is primarily based on clinical and radiographic findings, these methods may not fully reflect disease activity or progression.\n\nIn this observational study, individuals with periodontal health, gingivitis, and periodontitis will be included. Salivary levels of IL-17, IL-23, IL-6, TGF-β, RANKL, and OPG will be measured using ELISA. The relationship between these biomarkers and periodontal disease stage and grade will be analyzed.\n\nThe results are expected to improve understanding of the biological mechanisms underlying periodontal disease progression and to assess the potential role of salivary biomarkers in early diagnosis and personalized treatment approaches.",[27,211,31],"Gingivitis and Periodontal Diseases",[27,213,31,214,215,216,217,37,218,219,220,221,222],"Gingivitis","Salivary Biomarkers","Bone Remodeling","Interleukin-17 (IL-17)","Interleukin-23 (IL-23)","Transforming Growth Factor Beta (TGF-β)","RANKL","Osteoprotegerin (OPG)","ELISA","Non-invasive Diagnosis","2026-06-16",{"date":225,"type":42},"2026-06-22",{"date":227,"type":42},"2025-07-10",{"date":229,"type":23},"2026-08-30",{"name":231,"class":49},"Suleyman Demirel University",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":57,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":84},"100643006","mental-health-and-periodontitis-in-probable-bruxers-100643006","NCT07634250","Mental Health and Periodontitis in Probable Bruxers","Association Between Mental Health Status and Periodontitis Among Probable Bruxers","Inclusion Criteria:\n\n1. Adult periodontitis patients with age group 30-50 years diagnosed with probable bruxism.\n2. Presence of minimum 20 teeth excluding third molars.\n\nExclusion Criteria:\n\n* History of systemic disease such as diabetes or autoimmune disease\n* History of drugs having the potential impact on periodontal status like phenytoin, cyclosporin, calcium-channel blockers or antidepressant drugs.\n* Pregnant or lactating females.\n* Post-menopausal women.\n* Patients diagnosed with temporomandibular disorders- pain and tenderness in the masticatory muscles","30 Months","50 Months",{"count":242,"type":23},110,"The goal of this observational study is to learn how mental health affects periodontal health in people having teeth grinding (bruxism).\n\nThe main questions it aims to answer are:\n\nDoes poor mental health increase the risk of periodontitis in people with teeth grinding? Does stress link teeth grinding and periodontitis?\n\nParticipants are people who likely have teeth grinding(bruxism) and periodontitis\n\nParticipants will:\n\nAnswer questions about their mental health, including stress Get a periodontal health status check\n\nTeeth grinding(Bruxism) can occur due to stress, smoking, alcohol use, and bite problems. Stress may affect muscle activity and lead to teeth grinding. It can also weaken the body's defense and lead to poor oral care. This may worsen periodontal health.",[27],[246,247],"mental health status","probable bruxism","2026-06-03",{"date":250,"type":42},"2026-06-08",{"date":252,"type":23},"2026-06",{"date":254,"type":23},"2026-09",{"name":256,"class":49},"Postgraduate Institute of Dental Sciences Rohtak",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":121,"enrollmentInfo":265,"targetDuration":4,"studyType":95,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":84},"100643347","photodynamic-therapy-as-an-adjunct-in-periodontal-treatment-100643347","NCT07633405","Photodynamic Therapy as an Adjunct in Periodontal Treatment","Clinical Evaluation of Photodynamic Therapy as an Adjunct to Scaling and Root Planing in the Treatment of Periodontal Disease: A Split-Mouth Randomized Controlled Clinical Trial","PDT-PERIO","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of Stage I, II, III, or IV periodontitis according to the 2018 World Workshop Classification.\n* Presence of at least two hemiarches with periodontal pockets ≥5 mm suitable for a split-mouth design.\n* Systemically healthy individuals.\n* No periodontal treatment received within the previous 6 months.\n* No use of antibiotics, anti-inflammatory drugs, or antiseptic mouth rinses within the previous 3 months.\n* Ability and willingness to provide written informed consent and attend follow-up visits.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases that may affect healing or immune response.\n* Use of antibiotics, corticosteroids, or immunosuppressive medications within the previous 3 months.\n* Active smokers consuming more than 10 cigarettes per day.\n* Pregnant or breastfeeding women.\n* Presence of dental implants, defective restorations, or teeth with Grade III mobility in the selected study sites.\n* Known allergy to toluidine blue O or any component of the photosensitizer.\n* Individuals unable or unwilling to attend the 30-day follow-up visit.",{"count":94,"type":23},[125],"This study aims to evaluate the clinical effectiveness of antimicrobial photodynamic therapy (aPDT) as an adjunct to scaling and root planing (SRP) in the treatment of periodontitis. A split-mouth design will be used, in which one hemiarch receives conventional SRP and the contralateral hemiarch receives SRP combined with aPDT. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque index (PI), and gingival index (GI), will be assessed at baseline and 30 days after treatment. The study seeks to determine whether adjunctive aPDT improves periodontal outcomes compared with conventional non-surgical periodontal therapy alone.",[31,27],[31,27,270,271,272,273,274,275,276],"Antimicrobial Photodynamic Therapy","Photodynamic Therapy","aPDT","SRP","Clinical attachment level","Low level Laser therapy","Gingival Index","2026-06-02",{"date":250,"type":42},{"date":280,"type":23},"2026-07-28",{"date":282,"type":23},"2026-09-27",{"name":284,"class":49},"Universidad Catolica Santiago de Guayaquil",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":17,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":84},"100640638","oral-health-and-systemic-diseases-survey-of-general-practitioners-100640638","NCT07604493","Oral Health and Systemic Diseases: Survey of General Practitioners","Oral Health and Systemic Diseases: An Investigative Survey of General Practitioners","Inclusion Criteria:\n\n* Licensed General Practitioners currently practicing in Italy\n* Ability to understand and complete the questionnaire in Italian\n* Voluntary agreement to participate after reading study information and providing informed consent\n\nExclusion Criteria:\n\n* Physicians not currently practicing as General Practitioners\n* Incomplete questionnaire responses\n* Duplicate submissions\n* Participants who decline informed consent",{"count":148,"type":23},"This cross-sectional observational study aims to assess the level of knowledge, clinical practices, and professional attitudes of General Practitioners (GPs) regarding oral health and its relationship with major systemic diseases, with particular emphasis on periodontal disease. Data will be collected through an anonymous, self-administered digital questionnaire distributed nationwide to General Practitioners practicing in Italy. The questionnaire will investigate participants' knowledge of oral diseases, awareness of oral-systemic associations, early identification of oral manifestations, educational background, and interdisciplinary collaboration with dental professionals.",[27,295],"Diabete Mellitus",[297,298,102],"smoking","diabetes","2026-05-23",{"date":301,"type":42},"2026-05-28",{"date":303,"type":42},"2026-01-01",{"date":305,"type":23},"2027-01-01",{"name":307,"class":49},"University of Roma La Sapienza",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":84},"100637477","periodontal-disease-in-patients-with-lynch-syndrome-100637477","NCT07600710","Periodontal Disease in Patients With Lynch Syndrome","Periodontal Disease in Patients With Lynch Syndrome: a Retrospective Observational, Monocentric Case-control Study","SMILy_25","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. All sexes eligible\n3. Established diagnosis of LS performed as part of clinical practice, with a germline pathogenic\u002Flikely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM\n4. LS subjects undergoing surveillance gastrointestinal endoscopy according to clinical practice and international guidelines.\n5. Subjects underwent dental and periodontal examination\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Absence of sufficient periodontal clinical or radiographic data to establish a periodontal diagnosis;\n3. Subjects affected by systemic, autoimmune, chronic inflammatory, neurological, or severe psychiatric disorders, or by any other clinical condition that may interfere with study participation or data interpretation\n4. Subjects with systemic conditions known to strongly affect periodontal status (e.g. uncontrolled diabetes, autoimmune inflammatory diseases, ongoing cancer therapy) were excluded to reduce major confounding factors that could independently alter periodontal outcomes.",{"count":7,"type":23},"The field of human microbiome research has undergone a revolution in its approach toward understanding how microorganisms influence the physiology of their host 1. The influence of the oral microbiota is not confined to this location 2. Periodontitis is a \"chronic inflammatory disease associated with dysbiotic plaque biofilms and characterized by a progressive destruction of the tooth supporting apparatus\"3. Given these observations, the central research question of the present study is to determine the prevalence of periodontitis in patients with Lynch syndrome (LS) compared with reference prevalence estimates from the general population40.",[319,27],"Lynch Syndrome","2026-05-18",{"date":322,"type":42},"2026-05-22",{"date":324,"type":23},"2026-06-01",{"date":326,"type":23},"2026-07-31",{"name":328,"class":49},"Rotundo Roberto",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":95,"phases":338,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":356},"100637557","phase-1-a-novel-proline-rich-peptide-hydrogel-for-periodontal-regeneration-in-adult-periodontitis-patients-100637557","NCT07581613","A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration in Adult Periodontitis Patients","A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration: a Multicenter Parallel-arm Randomized Clinical Trial","PERIHEAL","Inclusion criteria\n\n* Adults \\>18 years with periodontitis (Stage III or IV)\n* Systemically healthy (ASA I or II)\n* Non-smokers or smoking \\\u003C10 cigarettes\u002Fday\n* Having undergone steps 1 (risk factor control, oral hygiene improvement including interdental hygiene) and 2 (subgingival instrumentation and biofilm control) of systematic periodontal therapy\n* Indication for step 3 periodontal therapy, i.e., sites with residual\u002Fpersistent pockets (PPD \\>5 mm and BoP or PPD \\>6 mm) around single- or multi-rooted teeth with mobility \\\u003Cgrade II at re-evaluation 8-12 weeks after non-surgical instrumentation (Step 2). Further site-specific criteria include at least one site with a radiographic infrabony defect (2- or 3-walled) with a \\>3 mm intrabony component, not associated with an open furcation, indicated for regenerative surgery\n* Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤20% before surgery\n\nExclusion criteria\n\n* Medical conditions contraindicating surgery\n* Pregnancy or lactation\n* Current use of systemic antibiotics\n* Smoking \\>10 cigarettes\u002Fday\n* FMPS or FMBS \\>20%\n* Mobility grade II or greater\n* Acute oral infections, active endo-perio lesions or active carious lesions on teeth associated with bone defects",{"count":180,"type":23},[339,340],"PHASE1","PHASE2","The goal of this clinical trial is to learn if a novel peptide-rich hydrogel works to achieve periodontal regeneration in adults. It will also learn about the safety of the hydrogel. The main questions it aims to answer are:\n\n* Does the novel peptide hydrogel achieve periodontal regeneration to a similar degree as another currently used therapy (hyaluronic acid)?\n* What medical problems, if any, do participants have when receiving the novel hydrogel treatment? Researchers will compare the novel peptide hydrogel to another commonly used hydrogel (hyaluronic acid) to see if the peptide hydrogel works to treat periodontal bone defects.\n\nParticipants will:\n\n* Receive the novel hydorgel or hyaluronic acid when they undergo periodontal regenerative surgery\n* Visit the clinic at regular intervals for 1 year after the surgery for follow ups",[27,343],"Intrabony Periodontal Defects",[345,346],"periodontal regeneration","hydrogels","2026-05-11",{"date":349,"type":42},"2026-05-14",{"date":351,"type":23},"2026-11-01",{"date":353,"type":23},"2030-06-30",{"name":355,"class":49},"Siddharth Shanbhag",2,{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":95,"phases":367,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":84},"100640966","comparison-between-different-interdental-brushes-in-adults-with-periodontal-disease-100640966","NCT07575997","Comparison Between Different Interdental Brushes in Adults With Periodontal Disease.","A Clinical Study Evaluating the Efficacy of an Interdental Brush Versus Comparators in Adults With Periodontal Disease.","Inclusion Criteria:\n\n* Subject aged between 18 and 80 years included\n* Subject having signed his\u002Fher written informed consent for his\u002Fher participation in the study\n* Subject diagnosed with active generalized periodontal disease (excluding gingivitis)\n* Subject having at least 20 natural teeth (10 teeth on each side (right and left))\n\nNon-inclusion criteria:\n\n* Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his\u002Fher consent in writing and to report required information in a questionnaire\n* For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study\n* Subject having any other oral condition than periodontal disease (ex: dermatologic ulcers), or any orthodontic conditions liable to interfere with the study assessment or considered by the investigator hazardous for the subject or incompatible with study requirements\n* Systemic treatment or topical treatment\u002Fproduct currently taken\u002Fapplied in the mouth liable to interfere with study assessments according to the investigator or planned to be taken\u002Fapplied during the study\n* Subject has received periodontal therapy (scaling, root planing, surgery, etc.) within 2 months before the inclusion\n* Subject who has undergone oral or gum surgery within 2 months before the inclusion, or planned to be performed during the study","80 Years",{"count":366,"type":23},88,[125],"The aim of this exploratory study is to evaluate the efficacy of the tested interdental brush versus comparative interdental brushes in adults with periodontal disease, over a 4-week period.",[27],[27,371],"Interdental Brushes",{"date":373,"type":42},"2026-05-08",{"date":375,"type":42},"2026-04-10",{"date":377,"type":23},"2027-06-30",{"name":379,"class":380},"Pierre Fabre Dermo Cosmetique","INDUSTRY",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":17,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":402,"locationsCount":84},"100638179","candida-albicans-in-syrian-patients-with-periodontitis-100638179","NCT07574827","Candida Albicans in Syrian Patients With Periodontitis","Prevalence and Impact of Candida Albicans in Syrian Patients With Periodontitis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Diagnosed with chronic periodontitis based on clinical examination (attachment loss, probing depth).\n* Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with systemic diseases affecting oral health (e.g., diabetes, immunosuppressive conditions).\n* Recent antibiotic or antifungal treatment within the last three months.",{"count":148,"type":23},"Periodontitis is a significant oral health issue characterized by inflammation and destruction of the supporting structures of the teeth. Recent research has indicated that Candida albicans, a common fungal pathogen, may play a role in the exacerbation of periodontal diseases. This study aims to investigate the prevalence and impact of Candida albicans in Syrian patients diagnosed with periodontitis, contributing to a better understanding of its role in oral health within this population.",[27,391,31],"Periodontal Diseases",[393,394,31,395,396],"Candida Albicans","Candida","Sabouraud Dextrose Agar","Culture","2026-05-02",{"date":373,"type":42},{"date":400,"type":42},"2026-04-07",{"date":254,"type":23},{"name":403,"class":49},"Al-Hawash Private University",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":17,"sex":18,"minAge":411,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":95,"phases":415,"briefSummary":417,"conditions":418,"keywords":422,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":4},"100635484","phase-3-periodontal-disease-and-small-vulnerable-newborns-in-rural-nepal-a-community-based-trial-100635484","NCT07553286","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Randomized Trial","Inclusion Criteria:\n\n* Married women of reproductive age (15-35 years).\n* Living in the study area who are pregnant and consent to participate.\n\nExclusion Criteria:\n\n* Currently pregnant women.\n* Women who are sterilized or use long-acting contraceptive methods or are divorced or widowed.\n* Women identified as pregnant ≥12 gestational weeks based upon date of last menstrual period.","15 Years","35 Years",{"count":414,"type":23},2280,[416],"PHASE3","Periodontal disease in pregnant women has been implicated as a potential risk factor for adverse pregnancy outcomes, including being born preterm, small-for-gestational age, and\u002For low birth weight. Infants who have at least one of these outcomes, known as small vulnerable newborns (SVN)), are at increased risk of early death and poor infant growth and development. Rigorous, high-quality randomized trials are needed to evaluate whether improving the periodontal health of pregnant women can reduce the risk of adverse pregnancy outcomes in areas like South Asia, where these outcomes are common and neonatal mortality remains high. This study is a community-based, randomized controlled trial (n=2,280) to evaluate a package of oral health interventions delivered to pregnant women in the first trimester until delivery on the incidence of SVNs in rural Sarlahi District, Nepal. The intervention package will include a daily antiseptic oral rinse and intensive oral hygiene education and instruction. Both intervention and control groups will be provided a manual toothbrush and toothpaste. The investigators will determine intervention effects on incidence of SVNs and individual outcomes of preterm birth, small-for-gestational age, and low birth weight. In a biospecimen sub-study (n=200), the investigators will collect venous blood, gingival crevicular fluid, and plaque in early and late pregnancy to explore relationships between subgingival inflammation, systemic inflammation, and SVN types and other adverse pregnancy outcomes. If efficacious, a low-cost package of oral health interventions - including an antiseptic oral rinse, intensive oral hygiene education and instruction, and provision of a manual toothbrush and toothpaste - could improve maternal and newborn outcomes at this critical time of growth and development.",[29,419,420,421,27],"Low Birth Weight","Small Vulnerable Newborn","Small-for-gestational Age",[423,424,425,426,427,428,429,28,430,431,213,432,433],"Nepal","Oral health","Small Vulnerable Newborns","Preterm birth","Periodontal disease","Low birth weight","Small-for-gestational age","Antenatal care","Dental health","Antiseptic oral rinse","Oral hygiene","2026-04-27",{"date":436,"type":42},"2026-05-01",{"date":438,"type":23},"2026-07-01",{"date":440,"type":23},"2028-12-31",{"name":442,"class":49},"Johns Hopkins Bloomberg School of Public Health",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":17,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":450,"targetDuration":452,"studyType":24,"phases":4,"briefSummary":453,"conditions":454,"keywords":455,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":470},"100624225","diagnostic-accuracy-of-oral-images-opgs-biomarkers-and-questionnaires-vs-clinical-assessment-for-periodontal-disease-postnct07164573-100624225","NCT07406867","Diagnostic Accuracy of Oral Images, OPGs, Biomarkers and Questionnaires vs. Clinical Assessment for Periodontal Disease (PostNCT07164573)","Diagnostic Accuracy of Oral Images, Orthopantomographs (OPGs), Biomarkers and Self-Reported Questionnaires vs. Clinical Assessment for Detecting Periodontal Health and Disease: a Multi-center Diagnostic Study","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Seeking dental care at one of the participating study centers.\n* Ability to understand and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Edentulous patients (complete tooth loss).\n* Pregnancy or lactation.\n* History of periodontal therapy (other than supragingival prophylaxis\u002Fcleaning) within the past 12 months.\n* Use of antibiotic medication within the 3 months prior to enrollment.",{"count":451,"type":23},2000,"1 Day","This multi-center, cross-sectional diagnostic trial evaluates the accuracy of multiple non-invasive screening tools-including self-reported questionnaires, intra-oral photographs, orthopantomographs (OPGs), intraoral scans (IOS), and salivary\u002Fmicrobial biomarkers-for detecting periodontal health and diseases (gingivitis and periodontitis Stages I-IV), using full-mouth clinical periodontal examination as the reference standard. A total of 2,000 participants will be recruited across five international centers. Diagnostic performance (sensitivity, specificity, AUROC) of individual and combined methods will be assessed using logistic regression and machine learning algorithms to establish an optimized multi-modal screening algorithm.",[27,213,31],[456,457,391,458,459,460],"Diagnosis","ArtiLcial Intelligence","Radiography","Machine Learning","Photography","2026-04-24",{"date":463,"type":42},"2026-04-30",{"date":465,"type":42},"2026-03-01",{"date":467,"type":23},"2029-03-01",{"name":469,"class":49},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",3,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":57,"minAge":478,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":84},"100628998","serum-inflammatory-protein-concentration-during-dental-treatment-100628998","NCT07468929","Serum Inflammatory Protein Concentration During Dental Treatment","Systemic Molecular Markers of Surgical Trauma in Periodontitis\u002FPeri-implantitis Patients","Inclusion Criteria:\n\n* Adults 21-75 years of age\n* Systemically healthy\n* Non-smoker\n* scheduled to receive nonsurgical or surgical periodontal treatment under IV sedation\n\nExclusion Criteria:\n\n* Patients who have localized form of the disease (less than 30% of available tooth\u002Fimplant sites are affected with the disease)\n* Non-english speaking individuals since informed consent form will be in English only.\n* Patients with uncontrolled systemic diseases (such as metabolic diseases, obesity, diabetes, high blood pressure) since these types of chronic inflammatory challenges would cause increase levels of circulatory serum pro-inflammatory markers.\n* Pregnant patients (pregnancy will be reported by the patient) since pregnancy itself would affect circulatory serum pro-inflammatory markers.\n* Patients who are not willing to have blood drawing for the study purpose.\n* Patients who are not willing to sign research related consent form.","21 Years","75 Years",{"count":94,"type":23},"The goal of this observational study is to study the molecular markers of stress in blood samples from people who are having periodontal surgery. The main question it aims to answer are:\n\n* How do the levels of inflammatory molecules in the blood change during a periodontal surgery?\n* How are the levels of inflammatory molecules in a person having surgery different from the levels in a person having a nonsurgical procedure?\n* Participants will be people who are having a periodontal surgery or a nonsurgical periodontal treatment as part of their dental care. Participants will be asked to let the investigator take blood samples from them before, during, and after the procedure is being done. The blood will later be analyzed for substances in the blood that are associated with inflammation.",[27,483],"Periodontal Surgery","2026-04-16",{"date":486,"type":42},"2026-04-20",{"date":488,"type":23},"2026-05",{"date":490,"type":23},"2027-02",{"name":492,"class":49},"Ohio State University",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":95,"phases":503,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":512,"leadSponsor":514,"locationsCount":84},"100621955","cheer-oral-health-in-pregnancy-study-100621955","NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study",{"count":502,"type":23},160,[125],"Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[213,506,28,507,508,27,73],"Dental Health","Pregnancy Outcomes","Randomized Controlled Trial","2026-04-01",{"date":400,"type":42},{"date":324,"type":23},{"date":513,"type":23},"2028-06-01",{"name":515,"class":49},"University of California, San Francisco",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":95,"phases":525,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":537,"leadSponsor":539,"locationsCount":84},"100627245","adjunctive-diode-laser-therapy-in-non-surgical-periodontal-therapy-100627245","NCT07446127","Adjunctive Diode Laser Therapy in Non-Surgical Periodontal Therapy","Evaluation of the Effect of Adjunctive Diode Laser Therapy in Mechanical Scaling and Root Surface Debridement in Non-Surgical Periodontal Therapy","Inclusion Criteria:\n\n1. Systemically healthy patients\n2. Each patient should have more than 20 teeth remaining, and at least 5 teeth per quadrant\n3. Each patient presented ≥ 30% of sites involved\n4. At least 2 teeth with a probing depth of ≥ 5 mm in each quadrant, with evident radiographic bone loss.\n\nExclusion Criteria:\n\n1. History of systemic diseases affecting the periodontium\n2. Smokers and alcoholic patients\n3. Use of medication within the last 6 months, which might affect the periodontal status\n4. Pregnant and lactating women\n5. Patients who had any periodontal treatment ≤ 12 months before the examination.",{"count":524,"type":23},20,[125],"The goal of this clinical trial is to evaluate the efficacy of adjunctive application of diode laser to mechanical, non-surgical root surface debridement in patients attending periodontal office. The main question it aims to answer is:\n\nTo compare the clinical effectiveness of adjunctive application of a 940-nm diode laser with root surface debridement to the effectiveness of root surface debridement alone.\n\nThis study is a split-mouth design, where each quadrant will be randomly allocated to one of the following groups:\n\nControl group (root surface debridement - RsD): scaling and root planing alone. Laser group (RsD + laser): scaling and root planing with adjunctive diode laser therapy Quadrants will be randomly allocated to the treatment groups",[27,528,529],"Periodontal Pockets","Periodontal Attachment Loss",[531,532],"diode laser","non surgical periodontal treatment","2026-02-25",{"date":535,"type":42},"2026-03-03",{"date":303,"type":42},{"date":538,"type":23},"2026-12-31",{"name":540,"class":49},"Tel Aviv University",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":549,"enrollmentInfo":550,"targetDuration":4,"studyType":95,"phases":551,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":84},"100598257","lactoferrin-based-oral-care-for-periodontal-health-in-pregnancy-100598257","NCT07069140","Lactoferrin-Based Oral Care for Periodontal Health in Pregnancy","Effectiveness of an Oral Care Protocol Based on Lactoferrin Toothpaste and Mouthwash in Pregnant Women for the Prevention of Periodontal Disease: A Randomized Controlled Clinical Trial","LBC-PREG","Inclusion Criteria:\n\n* Pregnant women aged between 18 and 45 years\n* Gestational age between 14 and 28 weeks at the time of enrollment (second trimester)\n* Diagnosis of periodontitis according to the 2017 World Workshop classification (Stages I-III, Grades A-B)\n* Presence of at least 20 natural teeth\n* Willingness to comply with study procedures and attend follow-up visits\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of systemic diseases that could affect periodontal status (e.g., diabetes mellitus, immunosuppression)\n* Antibiotic or anti-inflammatory therapy within 3 months prior to enrollment Current use of probiotics, antioxidant supplements, or medicated mouthwashes\n* Periodontal treatment within 6 months before enrollment\n* High-risk pregnancy or pregnancy complications (e.g., preeclampsia, gestational diabetes)\n* Smoking or tobacco use\n* Known allergy to any of the investigational product components\n* Participation in another clinical trial within the previous 3 months","45 Years",{"count":180,"type":23},[125],"This randomized controlled clinical trial aims to evaluate the effectiveness of a lactoferrin-based oral hygiene protocol in improving periodontal health during pregnancy. Forty pregnant women between the fourth and eighth month of gestation will be enrolled and randomly assigned to one of two groups. The trial group will undergo professional dental cleaning every three months and will perform home oral hygiene using both a lactoferrin-based toothpaste and a lactoferrin-based mouthwash (Emoform Glic) twice daily. The control group will follow the same schedule of professional dental cleanings but will use only the lactoferrin-based toothpaste (Emoform Glic) at home. The primary objective is to assess the reduction in dental plaque, measured by the Plaque Index (PI). Secondary outcomes include improvements in gingival inflammation, probing pocket depth, clinical attachment level, and other periodontal indices. Participants will be followed for six months, with evaluations conducted at baseline, 1, 3, and 6 months.",[28,27,213,554],"Oral Microbiota",[556,28,27,554,557,213,558,559,560,561,562,508,563],"Lactoferrin","Dental Plaque","Non-surgical Periodontal Therapy","Toothpaste","Mouthwash","LBC Complex","Maternal Oral Health","Oral Hygiene in Pregnancy","2026-02-19",{"date":566,"type":42},"2026-02-20",{"date":568,"type":42},"2025-07-30",{"date":570,"type":23},"2026-06-10",{"name":572,"class":49},"University of Pavia",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":95,"phases":582,"briefSummary":583,"conditions":584,"keywords":588,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":84},"100595200","effectiveness-of-coenzyme-q10-and-probiotics-in-periodontal-therapy-during-pregnancy-100595200","NCT07029360","Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy","Adjunctive Use of Coenzyme Q10 and Probiotics to Improve Periodontal Health in Pregnant Women: A Randomized Controlled Trial","PREG-Q10","Inclusion Criteria:\n\n* Pregnant women between the 4th and 8th month of gestation\n* Age ≥ 18 years\n* Able to understand and communicate in Italian and\u002For English\n* Willing to provide written informed consent\n* Good compliance and willingness to follow study instructions\n\nExclusion Criteria:\n\n* Presence of cardiac pacemakers\n* Diagnosed psychological, neurological, or psychiatric disorders\n* Ongoing oncological therapy\n* Use of bisphosphonates within the last 12 months\n* Poor motivation or low compliance\n* Substance abuse (drugs or alcohol) or lifestyle incompatible with study requirements",{"count":180,"type":23},[125],"This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The primary outcome is the reduction of the Plaque Index (PI), while secondary outcomes include Bleeding on Probing (BoP), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), gingival inflammation (MGI, PMGI), plaque distribution (PCR%, API), and gingival recession (R). The study duration is 6 months. The goal is to assess whether this combined therapy can promote a balanced oral microbiota and enhance periodontal health during pregnancy.",[28,27,213,557,585,586,587],"Probiotics","Coenzyme Q10","Microbiota",[589,590,586,557,591,213,592,587,593,554,594,595,596,28,597,585,508],"Bleeding on Probing","Clinical Attachment Loss","Gingival Inflammation","Limosilactobacillus reuteri","Non-Surgical Periodontal Treatment","Periodontal Therapy","Plaque Control","Plaque Index","Pregnant Women",{"date":566,"type":42},{"date":600,"type":42},"2025-07-01",{"date":570,"type":23},{"name":572,"class":49},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":611,"enrollmentInfo":612,"targetDuration":4,"studyType":95,"phases":614,"briefSummary":615,"conditions":616,"keywords":618,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":84},"100614681","evaluation-of-the-efficacy-of-subgingival-application-of-lovastatin-gel-as-an-adjunct-to-non-surgical-treatment-of-periodontitis-in-generally-healthy-smokers-and-non-smokers-patients-in-central-europe-100614681","NCT07282756","Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe.","Assessment of Changes in Clinical and Radiological Parameters in Gingival Pockets After Subgingival Application of Lovastatin Gel in Combination With SRP Procedure Compared to SRP and Placebo Gel Application in the Treatment of Periodontal Disease in Generally Healthy Non-smokers and Smokers From Central Europe: a Split-mouth Randomized Controlled Trial.","RCT","Inclusion Criteria:\n\n* generally healthy patients\n* diagnosed periodontal disease (at least one pair of non-adjacent sites with PD≥5 mm or CAL ≥4 mm and vertical bone loss ≥ 3 mm)\n* no history of periodontal disease treatment\n* no history of antibiotic use in the past 6 months\n* an eligible tooth must be alive, with no history of endodontic treatment\n* non-smoking (group I) or active smokers (group 2)\n\nExclusion Criteria:\n\n* Statin allergy\n* receiving systemic statin therapy,\n* alcoholics\n* immunocompromised patients\n* pregnant or breastfeeding women.","59 Years",{"count":613,"type":23},44,[125],"The aim of the study is to evaluate how a gel (1.2% lovastatin) applied under the gum improves the results of classic periodontal treatment (SRP-scaling, root planing).\n\nThe study involves two groups of adults diagnosed with periodontitis: the first group consists of generally healthy individuals who do not smoke tobacco. The second group consists of generally healthy individuals who have been smoking for at least 5 years. Before the study begins, each participant will undergo gum health measurements. Changes in these parameters will be monitored throughout the study. Two teeth will be selected for each participant:\n\n* a gel containing the medication will be applied under the gum of one tooth\n* a gel that looks similar to the medication but does not contain any medicinal substance will be applied under the gum of the second tooth.\n\nBefore applying the gel, each participant will undergo subgingival cleaning (SRP) to remove any debris that may prevent the medicine from working.\n\nThe study will last six months.\n\nExpected results:\n\n* all participants will experience an improvement in the condition of their gums after treatment\n* the effect of treatment will be better in non-smokers than in smokers\n* the treatment outcome will be better in the area where the medicated gel was applied compared to areas where the gel without medicinal substances was applied.",[391,31,27,617],"Smokers",[102,619,620,297,621],"statins","lovastatin","periodontal disease","2026-02-18",{"date":566,"type":42},{"date":625,"type":42},"2025-07-11",{"date":627,"type":23},"2026-12",{"name":629,"class":49},"Medical University of Silesia",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":17,"sex":57,"minAge":19,"maxAge":121,"enrollmentInfo":638,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":640,"conditions":641,"keywords":644,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":654,"locationsCount":84},"100625386","investigation-of-the-relationship-between-periodontitis-and-sleep-quality-100625386","NCT07421960","Investigation of the Relationship Between Periodontitis and Sleep Quality","An Evaluation of the Relationship Between Sleep Quality and Periodontitis","RBPSQ","Inclusion Criteria:\n\n* systemically healthy,\n* clinical diagnosis of periodontitis,\n* clinical diagnosis of periodontal health\n\nExclusion Criteria:\n\n* history of regular use of systemic antibiotics, anti-inflammatory, or antioxidant drugs (previous 6 months);\n* nonsurgical periodontal treatment (previous 6 months);\n* surgical periodontal treatment (previous 12 months);\n* presence of \\\u003C20 teeth;\n* current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy);\n* diabetes diagnosis; rheumatoid arthritis diagnosis; and pregnancy, lactating, or excessive alcohol consumption.",{"count":639,"type":23},48,"This project aims to investigate the relationship between periodontitis and sleep quality. Its originality lies in evaluating the association between periodontal status and sleep quality together with salivary interleukin-6 (IL-6), interleukin-6 (IL-10) IL-10, and pentraxin-3 levels. In particular, examining the relationship of sleep quality with biological, psychological, and lifestyle factors through periodontitis and salivary IL-6, IL-10, and pentraxin-3 levels has not been previously studied in the literature. Methodologically, periodontal status will be determined through clinical examination; participants' Pittsburgh Sleep Quality Index and Multidimensional Fatigue Inventory scores will be recorded; and salivary IL-6, IL-10, and pentraxin-3 levels will be measured. The obtained data will be compared using statistical analyses to determine the strength of the relationship between periodontitis severity and sleep quality. From a management perspective, the project will be conducted following approval from the ethics committee. In terms of broader impact, the results are expected to scientifically demonstrate the relationship between periodontitis and sleep quality, contribute to the adoption of a holistic health approach in clinical practice, and increase public health awareness. Additionally, the project is expected to provide a foundation for future research on the relationship between oral health and quality of life.",[31,27,642,643],"Sleep Quality","Fatigue",[645,646,647,102,648],"IL-6","IL-10","pentraxin","sleep quality","2026-02-12",{"date":564,"type":42},{"date":652,"type":42},"2026-02-10",{"date":373,"type":23},{"name":655,"class":49},"Uskudar University",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":17,"sex":57,"minAge":412,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":95,"phases":665,"briefSummary":666,"conditions":667,"keywords":669,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":84},"100612801","oral-spray-bacillus-spore-probiotics-for-periodontal-disease-prevention-and-supprotive-treatment-in-the-elderly-100612801","NCT07258303","Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly","Evaluating Safety and Efficacy of Oral-Spray Bacillus Spore Probiotics (LiveSpo Smile CARE) in Preventing and Supporting the Treatment of Periodontal Diseases in Elderly in Hanoi","Inclusion Criteria\n\n* Patients aged 35 years and older.\n* Patients diagnosed with periodontal disease based on clinical examination, including gingivitis and periodontitis.\n* Patients presenting with at least 10 natural teeth in the dental arch.\n* Patients with stable general health status and able to comply with study procedures.\n* Patients (or their legal guardians) who provide written informed consent and voluntarily agree to participate in the study.\n\nExclusion Criteria\n\n* Patients with unstable general health, acute systemic or oral diseases, or malignant conditions that may interfere with participation.\n* Patients who are currently receiving treatment for periodontal disease at specialized dental facilities.\n* Patients currently using any therapeutic or adjunctive products for the management of periodontal disease.",{"count":664,"type":23},90,[125],"Periodontal diseases are strongly associated with dysbiosis of the oral microbiome within the biofilm. Key pathogens, including Streptococcus mutans, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis, contribute to caries progression and periodontal inflammation. Given the limitations of antibiotic use and their potential side effects, probiotics represent a promising biological approach to restore microbial balance and support oral health.\n\nIn this study, researchers propose that direct application of probiotic spray into the oral cavity is safe and effective in alleviating typical symptoms of periodontal disease, particularly by reducing pathogenic bacterial density.\n\nThe objective of this study is to evaluate the safety and efficacy of a oral-spray Bacillus spore probiotics (LiveSpo Smile CARE), containing Bacillus subtilis ANA48 and Bacillus clausii ANA39 at a concentration of ≥ 1 billion CFU\u002FmL x 20 mL formulation, for the prevention and supportive treatment of periodontal disease.\n\nStudy Design:\n\n* Sample Size: 90 participants\n* Study Location: an elderly care center in Hanoi, Vietnam\n\nIntervention Description: A total of 90 eligible participants will be randomly assigned to two groups (n = 45 per group).\n\n* The Placebo Group will receive 0.9% NaCl physiological saline, spray twice daily (afternoon and evening), with two sprays per application at three sites (both dental arches and the front teeth), totaling six sprays per use, for four consecutive weeks.\n* The Smile Care Group will receive an oral-spray probiotics containing ≥ 1 billion CFU\u002FmL × 20 mL of Bacillus subtilis and Bacillus clausii (LiveSpo Smile CARE), administered with the same dosage and frequency as the placebo group.\n\nAll participants will receive blinded, coded spray bottles to ensure objectivity. Both groups will be instructed to use the same standardized toothpaste during the study period. Caregivers will monitor the health status of participants and record relevant information in their medical records. During the study, caregivers will be instructed not to provide any additional probiotic oral care products or the solution contains similar components.\n\nStudy Duration: 12-18 months.",[27,668],"Oral Deseases",[27,670,671,672,673,674],"The elderly","pathogenic bacterial densities","Bacillus","Spores","oral-spray probiotics","2026-01-19",{"date":677,"type":42},"2026-01-21",{"date":679,"type":42},"2025-12-20",{"date":681,"type":23},"2027-05-01",{"name":683,"class":380},"Anabio R&D",{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":17,"sex":57,"minAge":19,"maxAge":121,"enrollmentInfo":690,"targetDuration":452,"studyType":24,"phases":4,"briefSummary":692,"conditions":693,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":84},"100616971","association-of-periodontal-status-and-smoking-with-salivary-inflammasome-markers-100616971","NCT07312552","Association of Periodontal Status and Smoking With Salivary Inflammasome Markers","The Impact of Periodontal Status and Smoking on Salivary Inflammasome Levels: A Cross-Sectional Study",{"count":691,"type":23},116,"The aim of this study is to evaluate the relationship between periodontal status and salivary levels of the inflammasomes NOD-like receptor family, pyrin domain containing 3 (NLRP-3), NOD-like receptor family, pyrin domain containing 6 (NLRP-6), NOD-like receptor family, pyrin domain containing 12 (NLRP-12), NOD-like receptor family, CARD domain containing 5 (NLRC-5), interleukin-1 beta (IL-1β) and interleukin-10 (IL-10). Furthermore, this study aims to investigate whether the salivary levels of these inflammasomes may serve as potential diagnostic biomarkers for distinguishing individuals with periodontitis from those without. In addition, the potential role of smoking in modulating the relationship between periodontal status and salivary inflammasome levels will also be explored.",[31,27,694,695,696],"Periodontal Health","Smoking","Inflammasomes","2026-01-17",{"date":677,"type":42},{"date":700,"type":42},"2025-12-23",{"date":702,"type":23},"2026-07",{"name":655,"class":49}]